Skirt­ing a group of pi­o­neers, Gilead part­ners with gene-edit­ing up­start Pre­ci­sion Bio in hunt to cure hep B

7 years ago
Pharma

Vi­vo Cap­i­tal bags $635M for its new biotech pub­lic com­pa­ny fund

7 years ago
Financing

Mike Narachi gets a $19M shot at a new ap­proach to gene ther­a­py — and he has an­oth­er big mar­ket in mind

7 years ago
Financing
Startups

Vi­tal Ther­a­pies evis­cer­at­ed as PhI­II dis­as­ter forces it to dis­card sole as­set

7 years ago
R&D

Atre­ca banks a $125M mega-round as it builds a pipeline of an­ti­bod­ies for can­cer and pon­ders IPO tim­ing

7 years ago
Financing

Bris­tol-My­ers claims the lead in a race to de­vel­op a TYK2 drug, hop­ing to dis­rupt a huge mar­ket for ...

7 years ago
R&D

Take­da shut­ter­ing Chica­go com­plex with 1,000 staffers in lead-up to Shire merg­er

7 years ago
Deals

Gilead, Gala­pa­gos re­port com­pet­i­tive num­bers for first big PhI­II read­out for fil­go­tinib in rheuma­toid arthri­tis

7 years ago
R&D

Pfiz­er, Mer­ck KGaA tout PhI­II suc­cess for Baven­cio; Im­mun­sanT gets a new in­vest­ment from JDRF

7 years ago
News Briefing

A Mar­tin Shkre­li wannabe de­fends a big spike in drug price and earns a Twit­ter lash­ing from the FDA's com­mish

7 years ago
Pharma

GSK-backed sci­en­tif­ic team at UCSF says they found the im­mor­tal­i­ty switch in can­cer cells — and know how to turn it ...

7 years ago
Discovery

Mer­ck her­alds a rare Big Phar­ma suc­cess for an­tibi­ot­ic PhI­II, but it’s al­so a cau­tion­ary tale about the mar­ket

7 years ago
R&D
Pharma

Join­ing the ex­o­dus at Gilead, CMO An­drew Cheng makes the switch to biotech CEO — trig­ger­ing a cross-coun­try move ...

7 years ago
People

No­var­tis makes it of­fi­cial: Al­con is mov­ing its HQ from Texas to Gene­va ahead of a spin­off

7 years ago
Pharma

Fo­cus­ing on the tu­mor mi­croen­vi­ron­ment, On­coRe­sponse gar­ners $40 mil­lion for the next stage of the R&D jour­ney

7 years ago
Financing
Startups

An­a­lyst of­fers Am­gen a boost for its ri­val an­ti-BC­MA BiTE, blem­ish­ing GSK as well as CAR-T ri­vals Cel­gene and ...

7 years ago
Cell/Gene Tx

Acor­da shares crater af­ter ap­peals court dash­es re­main­ing hopes for sal­vaging Ampyra patents — gener­ics loom

7 years ago
Pharma

The Broad wins an­oth­er — per­haps fi­nal — bat­tle in the war over Feng Zhang's CRISPR patents

7 years ago
People
Pharma

NHS re­fus­es to cov­er Ocre­vus for pri­ma­ry pro­gres­sive MS; OxStem taps vet­er­an drug hunter Georg Ter­stap­pen as CSO

7 years ago
News Briefing

SEC ac­cus­es biotech bil­lion­aire Phillip Frost of join­ing a 'pump-and-dump' scheme that net­ted $27M

7 years ago
People

Chi­nese phar­ma pow­er­house Han­soh joins fledg­ling biotechs in the Hong Kong IPO line

7 years ago
Financing
China

Am­i­cus chief John Crow­ley is snubbed at the FDA on his lat­est pitch for quick drug re­view. He'll be back, but an­a­lyst ...

7 years ago
Pharma

A star can­cer sci­en­tist failed to dis­close in­dus­try pay­ments over the years — does that mat­ter so much?

7 years ago
People

Tra­di­tion­al­ists at Take­da spark a fam­i­ly feud with CEO Christophe We­ber over his $62B Shire takeover deal

7 years ago
Deals
First page Previous page 1011101210131014101510161017 Next page Last page
A service from the Financial Times